Literature DB >> 8831703

Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium.

G Berclaz1, A C Andres, D Albrecht, E Dreher, A Ziemiecki, B A Gusterson, M R Crompton.   

Abstract

We have recently reported the molecular characterization of a novel murine receptor PTK (myk-1), belonging to the eph-related family, whose expression was differentially regulated during mammary gland development and elevated in invasive mouse mammary tumours. In this communication we have investigated the cellular origin of myk-1 expression by in situ hybridisation and RNase protection. Murine antisense myk-1 probe specifically recognised ductal and alveolar epithelium in the resting mouse mammary gland. In normal human breast, the expression of htk, the human homologue, was also confined to the secretory luminal epithelial cells. RNase protection analysis of enriched luminal and myoepithelial cells prepared from human reduction mammoplasty tissue confirmed the luminal specificity. Elevated expression of htk was found in several human breast carcinoma cell lines as well as in primary, high grade, infiltrating, ductal carcinomas of the breast. The specific epithelial expression of the myk-1/htk receptor PTK suggest a specialised role of this eph-related PTK in the differentiation and/or maintenance of secretory epithelium in the adult.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831703     DOI: 10.1006/bbrc.1996.1442

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

2.  Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

Authors:  S Ram Kumar; Jasbir Singh; Guangbin Xia; Valery Krasnoperov; Loubna Hassanieh; Eric J Ley; Jeffrey Scehnet; Neil G Kumar; Debra Hawes; Michael F Press; Fred A Weaver; Parkash S Gill
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 3.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

4.  Clinical implications of EphB4 receptor expression in pancreatic cancer.

Authors:  Man Li; Zuowei Zhao
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

5.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Authors:  Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

6.  EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab.

Authors:  Dan Li; Shuanglong Liu; Ren Liu; Yue Zhou; Ryan Park; Kranthi Naga; Valery Krasnoperov; Parkash S Gill; Zibo Li; Hong Shan; Peter S Conti
Journal:  Mol Pharm       Date:  2013-11-07       Impact factor: 4.939

Review 7.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.

Authors:  Michael S Kinch; Kelly Carles-Kinch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.

Authors:  Dana M Brantley-Sieders; Aixiang Jiang; Krishna Sarma; Akosua Badu-Nkansah; Debra L Walter; Yu Shyr; Jin Chen
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

9.  Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.

Authors:  Yen-Ching Lee; Janeanne R Perren; Evelyn L Douglas; Michael P Raynor; Maria A Bartley; Peter G Bardy; Sally-Anne Stephenson
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

10.  Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer.

Authors:  S A Stephenson; S Slomka; E L Douglas; P J Hewett; J E Hardingham
Journal:  BMC Mol Biol       Date:  2001-12-21       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.